# US 2019/0169192 A1 · Purinone derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169192 A1
- Document ID: US20190169192A1
- Status: Published application
- Kind: A1
- Application number: 16/269,744
- Filed: 2019-02-07
- Published: 2019-06-06
- Earliest claimed: 2010-05-31
- Assignees: Ono Pharmaceutical Co., Ltd.
- Applicants: Ono Pharmaceutical Co., Ltd.
- Inventors: Shingo YAMAMOTO; Toshio YOSHIZAWA
- Web page: https://patentgrep.com/patent/US20190169192A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A pharmaceutical composition comprising a compound of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 19

A pharmaceutical composition comprising a compound of the following formula:
or a pharmaceutically salt thereof, and a pharmaceutically acceptable excipient.

### Claim 20 (depends on 18)

The pharmaceutical composition according to claim 18, which is a BTK inhibitor.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, which is a prophylactic agent and/or a therapeutic agent for a Btk-related disease.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21, wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, or a cancer.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22, wherein the cancer is a non-Hodgkin's lymphoma.

### Claim 24 (depends on 19)

The pharmaceutical composition according to claim 19, which is a BTK inhibitor.

### Claim 25 (depends on 24)

The pharmaceutical composition according to claim 24, which is a prophylactic agent and/or a therapeutic agent for a Btk-related disease.

### Claim 26 (depends on 25)

The pharmaceutical composition according to claim 25, wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, or a cancer.

### Claim 27 (depends on 26)

The pharmaceutical composition according to claim 26, wherein the cancer is a non-Hodgkin's lymphoma.